Edgar Filing: CYTOGEN CORP - Form 3

CYTOGEN CORP Form 3 May 19, 2008

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

Common Stock

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement CYTOGEN CORP [NASD:CYTO] À EUSA Pharma Inc (Month/Day/Year) 05/08/2008 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) HERITAGE GATEWAY (Check all applicable) CENTRE, Â 1980 S. EASTON **ROAD. SUITE 250** Director _X_ 10% Owner Officer (Street) Other 6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) _X_ Form filed by One Reporting Person DOYLESTOWN, PAÂ 18901 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. 4. Nature of Indirect Beneficial
Ownership
Form: (Instr. 5)
Direct (D)
or Indirect

36,093,873 (1)

D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

(I) (Instr. 5)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

2. Date Exercisable and 3. Title and Amount of 6. Nature of Indirect 1. Title of Derivative Security 4. 5. **Expiration Date** Securities Underlying Ownership Beneficial Ownership (Instr. 4) Conversion (Month/Day/Year) Derivative Security or Exercise Form of (Instr. 5) (Instr. 4) Price of Derivative Derivative Security:

Edgar Filing: CYTOGEN CORP - Form 3

Date Expiration Title Amount or Security Direct (D)

Exercisable Date Number of Shares (I)

(Instr. 5)

Reporting Owners

Relationships

Reporting Owner Name / Address

Director 10% Owner Officer Other

EUSA Pharma Inc

HERITAGE GATEWAY CENTRE 1980 S. EASTON ROAD, SUITE 250 DOYLESTOWN, PAÂ 18901

Â X Â Â

Signatures

/s/ Zoe Evans 05/08/2008

**Signature of Date

Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On May 8, 2008, the Reporting Person acquired all of the issued and outstanding shares of common stock, \$0.01 par value, of the Issuer pursuant to an Agreement and Plan of Merger, dated March 10, 2008, among the Issuer, the Reporting Person, and EUSA Pharma (USA),
- (1) Inc., a wholly-owned subsidiary of the Reporting Person. In the merger, EUSA Pharma (USA), Inc. merged with and into the Issuer. On May 8, 2008 a Form 25 was filed with the SEC to effect the delisting from The Nasdaq Global Market of the common stock of the Issuer. On May 9, 2008, a Form 15 was filed with the Securities and Exchange Commission (the "SEC") to suspend the Issuer's duty to file reports required by Section 13 of the Securities Exchange Act and to terminate the registration of the common stock of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2